Lexeo Therapeutics
This role involves independently designing and optimizing analytical methods for gene therapy vectors, including in-vitro cell culture and AAV transduction, to demonstrate potency. The position requires generating high-quality data to support assay qualification, validation, and regulatory submissions while collaborating with internal teams and external partners. The successful candidate will drive analytical strategy, troubleshoot technical risks, and ensure compliance with cGMP and regulatory standards.
Headquarters
New York, New York, United States
Company Size
11-50 employees
Founded
2018
Lexeo Therapeutics is a New York City-based, clinical-stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The company advances high-impact genetic medicine candidates targeting genetically mediated cardiovascular diseases—including Friedreich ataxia, arrhythmogenic cardiomyopathy, desmoplakin cardiomyopathy, and hypertrophic cardiomyopathy—as well as APOE4-associated Alzheimer's disease. Building on research from Weill Cornell Medicine and UC San Diego, Lexeo prioritizes efficient development, advanced manufacturing, and strategic partnerships to deliver curative genetic therapies.
Lexeo Therapeutics to Participate in the Leerink Global Healthcare Conference
2 weeks ago
Lexeo Therapeutics Announces Closing of Public Offering and
Oct 20, 2025
Lexeo Therapeutics Highlights FA and PKP2 Cardiac Gene Therapy Progress at Oppenheimer Conference
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Lexeo Therapeutics.
13% below the average for this role
Lexeo Therapeutics: Behind The Rebound (NASDAQ:LXEO)
Nov 6, 2025
Cell Potency Analytical Development Lead
Artiva Biotherapeutics
Senior Scientist - Lentiviral Vectors
Revvity Signals
Advisor, Analytical Development - Gene Therapy
Eli Lilly and Company
Senior Scientist I, Analytical Development, Biologics CMC
Exelixis
Associate Scientist II, Analytical Development
Forge Biologics
Scientist II - Molecular Analytics & NGS
UCB